Abstract
AIM: Recent studies show that human microbiomes play a significant role in the development of endometrial carcinoma, which is a common gynecological cancer affecting women of reproductive age. This review provides an extensive analysis of how the microbiome interacts with endometrial carcinoma while focusing on its impact on disease progression and potential therapeutic advancements. METHODS: Extensive literature research was conducted to examine how microbial dysbiosis affects endometrial cancer development. The research analyzed both animal model studies and clinical cohort data to assess how microbiome composition influences cancer risk and progression alongside treatment outcomes. The research explored possible microbiome interventions alongside the translational challenges they present. RESULTS: New research findings demonstrate that microbial imbalance contributes to endometrial cancer development through chronic inflammatory processes and estrogen metabolism changes while affecting immune system behavior in the tumor microenvironment. Scientists are exploring unique microbial patterns to serve as biomarkers for detecting diseases and predicting treatment outcomes. Microbiome-targeted strategies, including probiotics and diet changes, demonstrate the potential to enhance treatment results for individuals receiving immunotherapy and chemotherapy. CONCLUSIONS: This review examines the detailed interactions between the microbiome and endometrial carcinoma and outlines their importance in developing predictive models and innovative treatments. We explore both the obstacles faced in applying microbiome research to clinical settings and potential research paths that could speed up the integration of microbiome-based therapies into patient healthcare.